Skip navigation
Skip navigation

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, Dipti; Tam, Constantine S; Joshua, Douglas; Ho, Joy Phoebe; Szer, Jeff; Quach, Hang; Spencer, Andrew; Harrison, Simon; Mollee, Peter; Roberts, Andrew W; Horvath, Noemi; Lee, Cindy; Zannettino, Andrew; Brown, Ross; Augustson, Bradley; Jaksic, Wilfrid; Gibson, John; Kalff, Anna; Johnston, Anna; Trotman, Judith; Kalro, Akash; Grigoriadis, George; Ward, Chris; Prince, H Miles

Description

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is...[Show more]

dc.contributor.authorTalaulikar, Dipti
dc.contributor.authorTam, Constantine S
dc.contributor.authorJoshua, Douglas
dc.contributor.authorHo, Joy Phoebe
dc.contributor.authorSzer, Jeff
dc.contributor.authorQuach, Hang
dc.contributor.authorSpencer, Andrew
dc.contributor.authorHarrison, Simon
dc.contributor.authorMollee, Peter
dc.contributor.authorRoberts, Andrew W
dc.contributor.authorHorvath, Noemi
dc.contributor.authorLee, Cindy
dc.contributor.authorZannettino, Andrew
dc.contributor.authorBrown, Ross
dc.contributor.authorAugustson, Bradley
dc.contributor.authorJaksic, Wilfrid
dc.contributor.authorGibson, John
dc.contributor.authorKalff, Anna
dc.contributor.authorJohnston, Anna
dc.contributor.authorTrotman, Judith
dc.contributor.authorKalro, Akash
dc.contributor.authorGrigoriadis, George
dc.contributor.authorWard, Chris
dc.contributor.authorPrince, H Miles
dc.date.accessioned2017-03-23T05:04:20Z
dc.identifier.issn1444-0903
dc.identifier.urihttp://hdl.handle.net/1885/113758
dc.description.abstractWaldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.
dc.publisherWiley
dc.rights© 2017 Royal Australasian College of Physicians
dc.sourceInternal medicine journal
dc.subjectwaldenström macroglobulinaemia
dc.subjectibrutinib, bendamustine
dc.subjectlymphoplasmacytic lymphoma
dc.subjectmonoclonal gammopathy of undetermined significance
dc.subjectrituximab
dc.titleTreatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
dc.typeJournal article
local.identifier.citationvolume47
dc.date.issued2017-01
local.publisher.urlhttp://au.wiley.com/WileyCDA/
local.type.statusPublished Version
local.contributor.affiliationTalaulikar, D., The Australian National University
local.description.embargo2037-12-31
local.identifier.essn1445-5994
local.bibliographicCitation.issue1
local.bibliographicCitation.startpage35
local.bibliographicCitation.lastpage49
local.identifier.doi10.1111/imj.13311
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Talaulikar_Treatment_of_patients_2017.pdf705.81 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  20 July 2017/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator